Introduction {#Sec1}
============

More than half of children with idiopathic nephrotic syndrome (NS) develop frequent relapses or steroid dependence. These children require various immunosuppressants to prevent relapses of NS. Children with NS are therefore exposed to the risk of recurrent infections and are at high risk of severe infections because of their relatively immunocompromised state. These infections also have the potential to precipitate NS relapses.

Notably, upper respiratory viral infections are common and may precipitate or induce relapses of NS \[[@CR1]\]. Several reports have described relapse of NS related to influenza (flu) virus in a season of pandemic influenza \[[@CR2], [@CR3]\]. Guidelines recommend that these children should have flu vaccinations to reduce the risk of having serious infections \[[@CR4]\]. However, relapse of NS can reportedly occur after various vaccinations \[[@CR5]--[@CR10]\]. Although inactivated flu vaccinations could also precipitate relapses of NS \[[@CR11], [@CR12]\], no data are available on the relative risk of NS relapse related to flu vaccines.

We report a retrospective cohort study of children with NS who received inactivated subunit-antigen flu vaccination in our hospital, with a focus on relapses of NS related to flu vaccinations.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

We examined data from children who were enrolled in the NS database of the National Center for Child Health and Development in Tokyo, Japan. Children were eligible for this study if they were newly diagnosed with idiopathic NS between the ages of 6 months and 15 years and if their last relapse was steroid-sensitive NS (SSNS), regardless of history of steroid-resistant NS (SRNS). Excluded were children with NS secondary to nephritis and those with congenital NS. This study was conducted in accordance with the Declaration of Helsinki and with the ethical guidelines for Medical and Health Research Involving Human Subjects created by the Ministry of Health, Labor and Welfare in Japan. In accordance with these guidelines, informed consent was not obtained from patients or their parents for this study. The National Center for Child Health and Development Ethics Review Board approved this study (approval number: 1097).

Definitions {#Sec4}
-----------

In the present study, the definitions of general conditions in pediatric NS were made according to clinical guidelines issued by the Japanese Society for Pediatric Nephrology \[[@CR13], [@CR14]\]. Idiopathic NS in children was defined as hypoalbuminemia (serum albumin levels ≤ 2.5 g/dL) and severe proteinuria (≥ 40 mg/h/m^2^ in pooled nighttime urine or an early morning urine protein creatinine (Cr) ratio \> 2.0 g/g Cr). Complete remission was defined as a urine protein creatinine ratio \< 0.2 g/g Cr or ≤  − protein on dipstick testing of early morning urine for three consecutive days. SSNS was defined as complete remission in \< 4 weeks after starting daily prednisolone (PSL) therapy. The relapse of NS was defined as ≥ 3 + protein on dipstick testing of early morning urine for three consecutive days. Frequently relapsing NS (FRNS) was defined as two or more relapses within 6 months of the initial response, or more than four relapses within any 12-month period. Steroid-dependent NS (SDNS) was defined as two consecutive relapses during PSL tapering or \< 14 days after discontinuation of PSL therapy. SRNS was defined as the absence of complete remission after ≥ 4 weeks of daily PSL therapy.

The day of inactivated subunit-antigen flu vaccination was defined as day 0, and the period from the pre-vaccination to the post-vaccination days as − X to + Y, respectively. 'Day 0′ is not necessarily the timing when patients had an influenza vaccine for the first time since they developed NS. In our study, we included children who received several times of vaccinations. The NS relapse rate was defined as the number of relapses one person had within one year. The duration of rituximab (RTX) therapy was defined as the period from the day of rituximab administration to the day of B cell recovery (CD19 + B cell count of ≥ 1% of total lymphocytes).

Study design {#Sec5}
------------

We reviewed the following data: sex, age at onset of NS, age at first inactivated subunit-antigen flu vaccination, observation period, the total number of NS relapses, the total number of flu vaccinations, the total number of flu infections, use of RTX at first vaccination, and use of PSL at flu vaccinations. We also reviewed types of NS (SRNS, FRNS, SDNS); we reviewed renal histopathology (minimal change, focal segmental glomerulosclerosis, diffuse mesangial hypercellularity, or no history of renal biopsy) and also use of immunosuppressants at first vaccination (cyclosporine, mycophenolate mofetil, mizoribine, cyclophosphamide, tacrolimus).

We compared NS relapse rates between days − 180 and 0 (the day of flu vaccination) with relapse rates from days 0 to + 30, + 31 to + 60, + 61 to + 90, + 91 to + 120, and + 121 to + 180. Based on the background that the side effects of an inactivated vaccine generally occur within a month of its administration, we subdivided into the relapse rate in the post-vaccination period from days 0 to + 30. In addition, to compare with NS relapse rates between days − 180 and 0 as the controlled pre-vaccination period, it was decided to examine NS relapse rates between days 0 and + 180 during the post-vaccination period.

Vaccines {#Sec6}
--------

Our policy was to administer inactivated subunit-antigen flu vaccine to consenting children with NS, except during any period of PSL therapy of ≥ 2 mg/kg/day. The other exception was if the patient was in a relapse of NS. In Japan, children younger than 13 years generally have a flu vaccination twice per year and those older than 13 have a flu vaccination once per year. In children who received two vaccinations in the same year, we defined 'first flu vaccine' as only their first vaccination of the two. The details of antigen strains in inactivated flu vaccines between 2002 and 2015 are shown in the Supplementary Table.

Statistical analysis {#Sec7}
--------------------

The relapse rate of NS was calculated by the person-year method. The risk ratio between pre- and post-vaccination was calculated with 95% confidence intervals (CIs) on the basis of the person-year method. Risk ratios and their 95% CIs for the NS relapse rate were also estimated by generalized estimating equation (GEE) Poisson regression. This regression was adjusted for parameters, including treatment with various immunosuppressants or no treatment, treatment with RTX or no treatment, treatment with PSL or no treatment, and flu infection in the same flu epidemic season or no flu infection. All statistical analyses were performed using The SAS software package for Windows, release 9.4 (SAS Institute Inc. Cary, NC). A *p* value \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

Clinical characteristics {#Sec9}
------------------------

Available for assessment were 304 children with NS who were newly diagnosed between 2002 and 2015. Of these, 104 children (73 boys) received flu vaccines. The clinical characteristics of these children are shown in Table [1](#Tab1){ref-type="table"}. The total number of flu vaccinations was 208. Vaccination details are as follows: 49 children received one vaccination, 25 received two vaccinations, 18 received three vaccinations, seven received four vaccinations, four received five vaccinations, and one received seven vaccinations. No patients experienced fever or symptoms of an allergic reaction that required any treatment after flu vaccination, even though the quantity of the flu vaccine in Japan since 2011 was changed. One boy received an inactivated subunit-antigen flu vaccine; he was taking oral anti-allergic medicines because he had suffered from local swelling of the arm following a flu vaccination before the onset of NS. A greater proportion of patients were taking immunosuppressants at the time of flu vaccination (91.8%) of the 26 children with a history of SRNS than of the other 78 children who did not have a history of SRNS. Only those with complete remission at the time of flu vaccination were included. The use of immunosuppressants, however, was similar among the children with and without a history of SRNS (data not shown). We could not evaluate the infection rate of children with NS because there were no data from children who received no flu vaccines but did not contract the flu.Table 1Clinical characteristics of the patients*n* = 104Boy : Girl73 : 31Age at onset of NS (years)4.85 ± 3.87Age at first flu vaccination (years)7.76 ± 5.10Observation period (years)2.64 ± 2.20Renal histopathology MC62 (59.6%) FSGS10 (9.6 %) DMH7 (6.7 %) No history of renal biopsy25 (24.0%)Past history of NS type SRNS26 (25.2%) FRNS/SDNS87 (83.7%)From day  -- 180 \~  + 180 Total number of NS relapses (times)261 Total number of flu vaccinations (times)208Immunosuppressants at flu vaccination No43 (20.7%) Yes165 (79.3%) CsA104 (50.0%) MMF40 (19.2%) MZR31 (14.9%) CPM5 (2.4%) Tac2 (1.0%) RTX6 (2.9%) PSL49 (23.6%)*SRNS* Steroid resistance nephrotic syndrome, *FRNS* Frequent relapsing nephrotic syndrome, *SDNS* Steroid dependence nephrotic syndrome, *MC* Minimal change, *FSGS* Focal segmental glomerulosclerosis, *DMH* Diffuse mesangial hypercellularity, *CsA* Cyclosporine, *MMF* Mycophenolate Mofetil, *MZR* Mizoribine, *CPM* Cyclophosphamide, *Tac* Tacrolimus, *RTX* Rituximab, *PSL*; prednisolone

Comparison of the relapse rate between the pre- and post-vaccination periods, and the risk ratio for nephrotic syndrome relapse in the post-vaccination vs. pre-vaccination periods {#Sec10}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Compared with the relapse rate during the − 180 to 0 interval (1.19 times/person-year), the relapse rate was 1.23 during 0 to + 30 (risk ratio: 1.04, 95% CI 0.82--1.89, *p* = 0.88), 1.58 during + 31 to + 60 (risk ratio: 1.33, 95% CI 1.08--2.30, *p* = 0.18), 1.41 during + 61 to + 90 (risk ratio: 1.19, 95% CI 0.94--2.10, *p* = 0.45), 1.41 during + 91 to + 120 (risk ratio: 1.19, 95% CI 0.94--2.10, *p* = 0.45), and 1.32 during + 121 to + 180 (risk ratio: 1.11, 95% CI 0.98--1.76, *p* = 0.54) (Fig. [1](#Fig1){ref-type="fig"}). Multivariate analysis showed that being administered PSL (at first vaccination) was a significant independent risk factor associated with NS relapses in all periods (Table [2](#Tab2){ref-type="table"}). In 49 children with PSL, the difference in the relapse rate in each post-vaccination period was not significantly different compared with the relapse rate in the pre-vaccination period from days  -- 180 to 0 (data not shown). Moreover, these results did not change when we repeated the analysis with exclusion of data from children with a history of SRNS (data not shown). We examined data regarding times of flu vaccination. The mean age at vaccination in the group that was limited to a vaccine twice (83 times) was significantly younger compared with the group that was limited to a vaccine once (125 times) (10.5 ± 5.5 vs 7.3 ± 3.8 years, *p* \< 0.0001). In the once vaccination group, the relapse rate in the post-vaccination period from days 0 to + 30 was significantly higher than that in the pre-vaccination period. Compared with the relapse rate in the pre-vaccination period from days − 180 to 0, the difference in relapse rate in each post-vaccination period, except for from days 0 to + 30, was not significant (Fig. [2](#Fig2){ref-type="fig"}). However, in the twice vaccination group, the relapse rate in the post-vaccination period from days 0 to + 30 was significantly lower than that in the pre-vaccination period. Compared with the relapse rate in the pre-vaccination period from days − 180 to 0, the difference in relapse rate in each post-vaccination period, except for from days 0 to + 30, was not significant (Fig. [3](#Fig3){ref-type="fig"}). However, the event of NS relapse from days 0 to + 30 in the twice vaccination group only occurred three times in three children.Fig. 1Comparison of relapse rates between the pre-vaccination period from days  -- 180 to 0 and the post-vaccination period (univariate analysis). \*in the post-vaccination period from days 0 to + 30 (risk ratio: 1.04, 95% confidence intervals: 0.82--1.89, *p* = 0.88). ^†^in the post-vaccination period from days + 31 to + 60 (risk ratio: 1.33, 95% confidence intervals: 1.08--2.30, *p* = 0.18). ^‡^in the post-vaccination period from days + 61 to 90 (risk ratio: 1.19, 95% confidence intervals: 0.94--2.10, *p* = 0.45). ^§^in the post-vaccination period from days + 91 to + 120 (risk ratio: 1.19, 95% confidence intervals: 0.94--2.10, *p* = 0.45). \|\|in the post-vaccination period from days + 121 to 180 (risk ratio: 1.11, 95% confidence intervals: 0.98--1.76, *p* = 0.54). *n.s* not significantTable 2Risk ratio for NS relapse (Generalized estimating equation Poisson regression)for NS relapsesRisk ratio95% Confidence intervalThe post-vaccination period (days 0 to  + 30)1.020.64--1.62The post-vaccination period (days  + 31 to  + 60)1.30.86--1.98The post-vaccination period (days  + 61 to  + 90)1.160.74--1.80The post-vaccination period (days  + 91 to  + 120)1.140.73--1.77The post-vaccination period (days  + 121 to  + 180)1.090.77--1.54On Immunosuppressants (reference: no immunosuppressants)0.860.62--1.20On RTX (reference: no RTX)1.110.50--2.49On PSL (reference: no PSL)3.012.18--4.17Flu infection (reference: no infection)2.380.81--6.99*NS* Nephrotic syndrome, *RTX* Rituximab, *PSL* prednisoloneFig. 2Comparison of relapse rates between the pre-vaccination period from days  -- 180 to 0 and the post-vaccination period in children who received a flu vaccination (univariate analysis). \*in the post-vaccination period from days 0 to + 30 (risk ratio: 1.82, 95% confidence interval: 1.07--3.08, relapse rate: 1.75, *p* = 0.027). ^†^in the post-vaccination period from days + 31 to + 60 (risk ratio: 1.31, 95% confidence interval: 0.72--2.39, relapse rate: 1.27, *p* = 0.38). ^‡^in the post-vaccination period from days + 61 to 90 (risk ratio: 1.21, 95% confidence interval: 0.65-- 2.25, relapse rate: 1.17, *p* = 0.55). ^§^in the post-vaccination period from days + 91 to + 120 (risk ratio: 1.21, 95% confidence interval: 0.65--2.25, relapse rate: 1.17, *p* = 0.55). ^∥^in the post-vaccination period from days + 121 to 180 (risk ratio: 1.11, 95% confidence interval: 0.68--1.81, relapse rate: 1.07, *p* = 0.68). *n.s* not significantFig. 3Comparison of relapse rates between the pre-vaccination period from days  -- 180 to 0 and the post-vaccination period in children who received two vaccinations in the same year (univariate analysis). \*in the post-vaccination period from days 0 to + 30 (risk ratio: 0.29, 95% confidence interval: 0.09--0.93, relapse rate: 0.44, *p* = 0.036). ^†^in the post-vaccination period from days + 31 to + 60 (risk ratio: 1.35, 95% confidence interval: 0.76--2.42, relapse rate: 2.05, *p* = 0.31). ^‡^in the post-vaccination period from days + 61 to 90 (risk ratio: 1.16, 95% confidence interval: 0.63--2.16, relapse rate: 1.76, *p* = 0.64). ^§^in the post-vaccination period from days + 91 to + 120 (risk ratio: 1.16, 95% confidence interval: 0.63--2.16, relapse rate: 1.76, *p* = 0.64). ^∥^in the post-vaccination period from days + 121 to 180 (risk ratio: 1.11, 95% confidence interval: 0.69--1.80, relapse rate: 1.69, *p* = 0.66). *n.s* not significant

Discussion {#Sec11}
==========

In our retrospective cohort study, we showed that inactivated subunit-antigen flu vaccination caused a slight, but nonsignificant increase in the risk of NS relapse (1.2 to 1.3--1.5 times in one person within a year) in children. Because the relapse rate in the post-vaccination period from days 0 to + 30 in the once vaccination group was significantly higher than that in the pre-vaccination period, we consider that flu vaccination might be prone to precipitating relapse of NS in older children who have flu vaccine once a year. Furthermore, inactivated subunit-antigen flu vaccination in children with NS did not precipitate SRNS or other severe adverse events. Our results suggest that these children can be immunized without a significantly increased risk of NS relapse. To the best of our knowledge, this is the first published study of NS relapses and other adverse effects related to flu vaccination.

In the present study, the relative risk of NS relapses was not significantly increased in the post- flu vaccination period compared with the pre-vaccination period. A small study of NS relapses in 19 children \[[@CR12]\], which used inactivated split-virion influenza vaccine same as Japan, reported one relapse episode three months after flu vaccination and three episodes of relapse six months after regarding the rate of NS relapse due to flu vaccination. Fernandes et al. \[[@CR11]\] reported a woman with NS had relapsed after monovalent whole-virion inactivated influenza vaccination \[[@CR11]\]. If we investigate the NS relapse associated with those different types of flu vaccines, we may get different results from the present study. NS relapses following the administration of other vaccines have also been reported. Abeyagunawardena et al. \[[@CR8]\] showed an increased risk of NS relapse following meningococcal C conjugate vaccine administration \[[@CR8]\]. It was suggested that the decision to administer the meningococcal C conjugate vaccine should be carefully considered in children with SSNS. Yildiz et al. \[[@CR9]\] suggested that patients with SSNS in hepatitis B virus (HBV) endemic regions should receive HBV vaccines because of the risk of HBV infections. They also suggested that HBV vaccines might trigger NS relapses in some pediatric patients with NS \[[@CR9]\]. To date, however, no reports have evaluated the details of relapses, such as the risk ratio of NS relapses, related to flu vaccination.

In the current study, inactivated subunit-antigen flu vaccination in children with NS was not associated with severe adverse events. While an allergic reaction is a serious concern for immunized patients, none of the children in our study had these symptoms. Although approximately one-quarter of the children in this study had a history of SRNS, NS relapses were all steroid-sensitive between approximately days − 180 and + 180. This suggests that no children who experienced relapses of NS became steroid-resistant after receiving an inactivated subunit-antigen flu vaccine. In another study, NS relapses after receiving varicella-zoster vaccines were all steroid-sensitive \[[@CR7]\].

An immunogenic stimulus may trigger NS relapse in children. The major pathogenesis of NS relapses related to various infections or vaccinations may involve activation of T cells in an acute process \[[@CR2], [@CR8]\]. However, the precise mechanism of this pathogenesis has not been biologically demonstrated. In the present study, we found a significantly high risk of NS relapse in children who were treated with steroids at the first vaccination. Flu vaccination in children taking steroids may occur soon after the last relapse of NS. If they are taking steroids when they have their flu vaccination, they may be susceptible to further NS relapse during this period. Therefore, this result may be not because of the steroids, but due to it been soon after the relapse.

Flu infections have the potential to become severe \[[@CR15]\], but the administration of flu vaccines is effective in reducing the prevalence of flu infections and the risk of severe flu infections. Notably, inactive immunizations are effective against pediatric patients with NS, even when they are being treated with glucocorticoids or other immunosuppressive drugs \[[@CR16]\]. Poyrazoglu et al. \[[@CR12]\] showed that pediatric patients with NS had adequate antibody responses to flu vaccination at 6 months post-vaccination compared with healthy controls \[[@CR12]\]. Although the present study was not intended to evaluate the efficacy of flu vaccination in preventing severe flu infections, none of the children in our study suffered from any severe infections.

There are several limitations to the present study. It was a retrospective chart review in a single center and comprised of a limited number of patients. A randomized, controlled trial is ideal for evaluating risk ratios for NS relapses regarding flu virus vaccines. A study is required, with the primary outcome of the relative rate of NS relapse in children with flu vaccination compared with those without flu vaccination. However, the feasibility of this type of randomized, controlled trial is low owing to the difficulty in establishing the side effects of vaccinations as a primary endpoint. A second limitation of this study is that selection bias may have resulted from the fact that our hospital is a tertiary institution, and a high proportion of severe patients were referred to this hospital. Therefore, we need to be careful if applying our results to all children who do not have FRNS or SDNS at a general hospital. A further limitation is that the 180 days of pre- and post- flu vaccination occurred from approximately fall to winter, when several infectious diseases become prevalent, and these infections could have resulted in NS relapses. In our study, we did not have data concerning other infections. A final limitation is that we did not examine the efficacy of the flu vaccinations because there was no data of children who received no flu vaccines but did not contract the flu.

In conclusion, inactivated subunit-antigen flu virus vaccination in children with NS produces a slightly increased, but nonsignificant, risk of relapse. Our results suggest that flu vaccines should not be avoided in children with NS for fear of potential NS relapses and other adverse events. Flu vaccination in children taking steroids may occur soon after the last relapse of NS. Therefore, providing flu vaccination soon after the last relapse of NS might risk further relapse. At the same time, pediatric nephrologists should consider a minimal increase in relapse due to vaccination against the substantial risk of flu infection and its consequences.
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